Follow the latest coverage, related explainers and connected technology stories.
The U.S. Food and Drug Administration is developing guidance for using generative artificial intelligence in medical devices, focusing on competency-based evaluation, foundation models, and post-market monitoring. Fundamental questions remain open about the limits of oversight and companies’ responsibility for declining model performance over time.
French company Mistral AI raised $3.5 billion in a Series D round led by Samsung Electronics, lifting its valuation to more than $24 billion and preserving its position as Europe’s most valuable company developing foundational artificial intelligence models.
The U.S. Food and Drug Administration has updated its list of AI-enabled medical devices authorized for marketing in the United States, emphasizing that the list is not exhaustive and does not represent a complete database of all devices. The agency is exploring future mechanisms to identify devices that incorporate foundation models, including large language models and multimodal systems.